Immunotherapy has been one of the most promising advancements in cancer treatment. However, consistency in immunotherapy ...

T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...

Scientists have found that preserving lymph nodes during cancer surgery could dramatically improve how patients respond to ...

Scientists have uncovered a sweet twist in the body’s fight against cancer. Glucose, best known as the fuel that powers our cells, also helps immune cells called T cells communicate and organize their ...

Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...

“Exhausted” refers to the fact that they’re part of the exhausted T cell lineage, which emerges when the immune system is constantly exposed to threats (such as tumor cells) and starts to wear out. So ...

Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

A protein notorious for its role in Alzheimer’s disease may hold the key to supercharging the aging immune system, according to new research. Scientists have found that a byproduct of amyloid-beta ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain ...